Genta, Inc (fka GNTAQ)

[The Holder]

We need to start doing some research on Genta's relationship with the US NCI. It looks like their about to get a boat load of money for cancer research.

http://www.boston.com/news/nation/washington/articles/2009/02/25/obama_cancer_cure_vow_requires_more_funds_experts/?rss_id=Boston.com+--+Latest+news

I can find something that mentions a research and development agreement with the NCI in 2005 for Genasense...I feel like Genta is about to get a financial shot in the arm from the National Cancer Institute.

http://www.drugs.com/nda/genasense_051229.html

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense to evaluate its potential to treat various forms of hematologic cancers and solid tumors. In addition, Genta has established a Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI).

Genasense® (oblimersen sodium) Injection has been in clinical trials since 1995 in the U.S., Europe and Australia, with efficacy and safety data from Phase 1, Phase 2 and Phase 3 clinical trials. More than 2,200 patients have entered randomized trials (one-half of whom were controls) and approximately 500 patients have been treated in non-randomized Phase 2 trials sponsored by Genta, through a long-standing Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI), or the European Organization for the Research and Treatment of Cancer (EORTC).

Clinical Trials Tab:
http://www.genta.com/clinical_development/genasense.php?v=6&PHPSESSID=82ae55518847e22a3896f10a2a83cb25